Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Evaluation of De-escalated Adjuvant Radiation Therapy for Human Papillomavirus (HPV)-Associated Oropharynx Cancer

Completed phase 3 DART trial (n=228) of de-escalated adjuvant RT plus docetaxel versus standard adjuvant RT in HPV-associated OPSCC. ctHPVDNA MRD was not used to assign treatment; a 140-patient secondary analysis is PMID 40402484.

Mayo Clinic